|
Thyroid carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Falsely elevated thyroglobulin and calcitonin due to rheumatoid factor in non-relapsing thyroid carcinoma: A case report.
|
30702570 |
2019 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
|
30785995 |
2019 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Endogenous thyroid-stimulating hormone-stimulated thyroglobulin collected after total thyroidectomy is a useful predictor of better prognosis in patients with differentiated thyroid carcinomas in general, but studies with microcarcinomas are scarce.
|
29157630 |
2019 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Finally, the application values of serum Tg, TgAb and ultrasound in the diagnosis of postoperative recurrence of thyroid cancer were analyzed.
|
29442477 |
2019 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer.
|
31444962 |
2019 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Fine needle aspiration cytology (FNAC) and washout thyroglobulin (Tg) measurements are the standard for evaluating a metastatic lymph node (LN) in thyroid cancer.
|
30959821 |
2019 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Regression models with asymmetric data for estimating thyroglobulin levels one year after the ablation of thyroid cancer.
|
29557257 |
2019 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer.
|
30396251 |
2018 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Histologically and immunohistochemically, the tumors resembled poorly differentiated thyroid cancers in humans, demonstrating a solid growth pattern with sheets of round or spindle-shaped cells, decreased expression of thyroglobulin, and a tendency to lose E-cadherin.
|
30125543 |
2018 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Extrapolation to other solid cancers demonstrated highly recurrent and tumor-type-specific indel hotspots targeting the noncoding regions of highly expressed genes defining certain secretory cellular lineages: albumin (ALB) in liver carcinoma, gastric lipase (LIPF) in stomach carcinoma, and thyroglobulin (TG) in thyroid carcinoma.
|
28089356 |
2017 |
|
Thyroid carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas.
|
28137736 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We measured serum Tg and Cyfra 21.1 6 to 12 months after primary treatment in 473 DTC patients.
|
28779086 |
2017 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Studies analyzing mortality from thyroid cancer should stratify patients into the various risk categories based on full baseline data, including postoperative thyroglobulin levels.
|
28791923 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Hence, accurate TgAb measurement, in addition to Tg quantification, is crucial for thyroid cancer monitoring.
|
28672730 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to compare the diagnostic performances of sonography plus suppressed or stimulated Tg in low-risk thyroid cancer.
|
28543974 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Despite this limitation, Tg remains the sole widely used thyroid cancer biomarker in the clinical setting.
|
28493290 |
2017 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic <sup>131</sup>I in the differentiated thyroid cancers.
|
27144920 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Posttreatment surveillance of thyroid cancer is done with US of the thyroid bed as well as monitoring of tumor markers such as serum thyroglobulin and serum calcitonin.
|
27618325 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the usefulness of Thyroglobulin measurement in FNAB washout (FNAB-Tg) in the detection of local metastasis in patients affected by or evaluated for thyroid cancer.
|
28558632 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prevalence and Significance of Thyroglobulin Antibodies in Pediatric Thyroid Cancer.
|
28398507 |
2017 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Factors associated with the higher amount of radiation exposure from the patients to the household environment were patient body weight (P = .025, univariate analysis; P = .037, multivariate analysis, odds ratio [95% confidence interval] 1.067 [1.004-1.134]) and distant metastases based on I post-therapy scanning (P = .041, univariate analysis; P = .058, multivariate analysis, odds ratio [95% confidence interval] 6.453 [0.938-44.369]); age, sex, body mass index, renal function, serum stimulated thyroglobulin level, and recombinant human thyroid-stimulating hormone use were not associated with the amount of radiation exposure from the patients to the household environment.Higher body weight and distant metastases may be the best predictors for higher radiation exposure to the household environment from patients with thyroid cancer after RAI therapy.
|
28858122 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
All patients with follicular cell-derived thyroid cancer (TC) who had thyroglobulin measured using LC/MS assay from November 1, 2013, to November 7, 2014, were evaluated.
|
27736322 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.
|
27236916 |
2016 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The diagnosis of thyroid carcinoma in pleural fluid can be particularly challenging as thyroid transcription factor -1 (TTF-1) which is a marker for carcinoma of thyroid origin is also positive in lung adenocarcinomas (which are more frequently associated with pleural effusions) and thyroglobulin (TG) can often be negative in poorly differentiated/analplastic thyroid carcinomas.
|
27456348 |
2016 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Phospho-PKM2 and Phospho-LDHA could be valuable tumour markers for thyroglobulin negative thyroid cancer.
|
25880801 |
2015 |